Paratek Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of life-saving therapies for life-threatening diseases or other public health threats for civilian, government, and military use. Its lead product candidates include NUZYRA, a once-daily oral and intravenous broad-spectrum antibiotic for the treatment of adult patients with community-acquired bacterial pneumonia and acute bacterial skin and skin structure infections caused by susceptible pathogens; and SEYSARA, a tetracycline designed for the treatment of moderate to severe acne vulgaris. The company has license and collaboration agreements with Zai Lab (Shanghai) Co., Ltd. and Allergan plc; license agreement with Tufts University to develop and commercialize products for the treatment or prevention of bacterial or microbial diseases, or medical conditions; and contract with Biomedical Advanced Research and Development Authority to support the development of NUZYRA for the treatment of pulmonary anthrax. In addition, it has license agreement with Tetraphase Pharmaceuticals, Inc. to develop, import, and sell the XERAVATM product, which is used for the treatment of complicated intra-abdominal infections caused by bacteria. Paratek Pharmaceuticals, Inc. was founded in 1996 and is headquartered in Boston, Massachusetts.

Paratek Pharmaceuticals, Inc.

Paratek Pharma develops and commercializes NUZYRA, an FDA-approved tetracycline-class antibiotic designed to address unmet needs for adult patients with CABP and ABSSSI caused by susceptible bacteria.

Paratek Pharma

Positive outcomes. Positive patient stories. These are our priorities at Paratek Pharmaceuticals. As a commercial-stage biopharmaceutical company, we develop transformative solutions for patients with infectious diseases and other difficult to treat conditions, and we believe that we have the right people, the right knowledge and the right drug to make a difference in patients’ lives.

Our Mission
To create positive stories for patients, physicians and caregivers based on trust and integrity. To accomplish this, our employees work hard to turn everyday decisions into everyday triumphs that advance our technology and strengthen Paratek.

Our Vision
To be a leading independent biopharmaceutical company providing novel life-saving products for life-threatening diseases or other public health threats.

The Baupost Group

Abingworth

Aisling Capital

Omega Funds

CBC Group

Biomedical Advanced Research and Development Authority (BARDA)

D. E. Shaw & Co.

IBT Management Corporation

Pacific Growth Equities

Paratek Pharmaceuticals

An expert advisory panel convened by ASHP Foundation provides recommendations for antimicrobial stewardship in the emergency department, particularly for the selection of oral antibiotics for adults with skin and soft tissue infections. 

We provided an educational grant to encourage this important dialogue as part of our commitment to helping reduce antimicrobial resistance. https://bit.ly/3YovfJR 

#Antibiotics #AMR #InfectiousDiseases

Paratek is proud to have participated in a back-to-school supply collection in support of St. James Outreach House. With the help of our amazing team in King of Prussia, we gathered essential school supplies to ensure that local children start the school year equipped and ready to learn.
 
The St. James Outreach House relies on donations and volunteer support to help the community and we’re grateful for the opportunity to support their mission and help families in need.
 
Thank you to everyone who contributed and to The St. James Outreach House for their incredible work. Together, we’re making a difference! We hope everyone has a great year of learning!
 
#CommunitySupport #BackToSchool #ParatekProud

As the summer comes to a close, we want to express our gratitude to our incredible interns. Your energy, creativity, and dedication have inspired the entire Paratek team. 
  
We are immensely proud of your contributions during your time with us and are excited to see the impact you'll continue to make in the future. Thank you for your hard work and enthusiasm. 
  
Paratek wishes you all the best in your academic and professional journeys ahead! #SummerInterns #FutureLeaders #Internships

Join Paratek at the American Podiatric Medical Association (APMA) National Annual Scientific Meeting in Washington, D.C. from August 8-10. 
 
Visit us at Booth 815 in the Washington D.C. Convention Center to talk to us about the role our product plays in the treatment of ABSSSI (Acute Bacterial Skin and Skin Structure Infections).  
 
You can find us on the interactive map here: https://bit.ly/4fpFMuu  
We look forward to seeing you there! 
  
#APMA2024 #APMANational2024 #AMR

We’re proud to have joined the healthcare community in recognizing #WorldNTMAwarenessDay. 
 
Together, we’re raising awareness of nontuberculous mycobacterial (NTM) pulmonary disease to support patients and families impacted by NTM, and advocating for better resources and earlier detection to avoid delayed diagnoses.  
 
A big thank you to the dedicated team and the ongoing commitment to finding better treatments for patients with #NTM.  
 
Learn more about our efforts: https://bit.ly/4fr4drk  
 
#NTMCommunity

Sending best wishes to the Olympic Team USA 8-man rowers including Peter Chatain, son of Paratek field sales representative, Kim Chatain. They’ll be rowing in the finals this Saturday, 8/3. 

We’re rooting for you stateside, Peter! 

Tune in to watch the race live at 5:10 a.m. ET: https://bit.ly/3WxmUku 

#TeamUSA #Olympics #Rowing

Paratek Pharmaceuticals has completed a five-year microbiologic surveillance study of its antibiotic, showing no change in in vitro potency and no emergence of resistance.

As part of our commitment to addressing antimicrobial resistance (AMR), we’re continuing surveillance studies.

See Paratek’s press release: https://bit.ly/4fsK1FK 

Biomedical Advanced Research and Development Authority (BARDA)
U.S. Department of Health and Human Services (HHS)

#drugdevelopment #biopharma #AMR

ICYMI: The 2024 Vivli #AMRSurveillance Data Challenge submission deadline has been extended until August 11!

Join the fight against anti-microbial resistance (AMR), a critical public health issue and contribute to life-saving research – and the chance to earn monetary awards to support your research. 

Learn more: https://bit.ly/3zZKdMs 

#sponsors #antibiotics #healthcare

Diane Anastasiou MT (ASCP), Director, Microbiology, is a judge for the 2024 Vivli #AMRSurveillance Data Challenge.

As proud supporters of this organization and this challenge, we understand firsthand the importance of sharing and analyzing #AMR data to advance research to develop solutions to combat this growing global health crisis. #sponsors

Deadline for submissions is Sunday, July 28. Learn more and help combat anti-microbial resistance.

#Antibiotics #healthcare

At Paratek, our people are the source and foundation of our innovation and culture. Joanne Tatem, Ph.D., Executive Director of Project Management, is one of those people. Bringing more than 25 years of industry experience with increasing leadership responsibility, Joanne has leveraged that significant expertise at Paratek leading projects and partnerships that make a significant impact for our business, customers and patients. Earlier this year, she received the 2024 Levy-Gilbert CEO Award to recognize her achievements and commitment to Paratek’s values.

msh id	COM:PARATEKPHARMA
symbol	PRTK
name	Paratek Pharmaceuticals, Inc.
homepage url	https://paratekpharma.com
country	US
sector	Healthcare
industry	Biotechnology
market	STOCKS
employee count	268
crunchbase url	-
linkedin url	-
founders	-

market cap	127.83M
enterprise value	-
stage	-
raised capital	-
valuation	-

monthly webtraffic	-
monthly webtraffic growth	-
growth score 14	-
growth score 28	-
growth score 90	-
growth score 365	-

revenue ltm	-
gross profit ltm	-
ebitda ltm	-
net income ltm	-
revenue ntm	-
gross profit ntm	-
ebitda ntm	-
net income ntm	-

growth cost and expenses	0.22
growth cost of revenue	0.07
growth depreciation and amortization	1.94
growth ebitda	-0.1
growth ebitda ratio	0.11
growth eps	-
growth eps diluted	-
growth general and administrative expenses	-
growth gross profit	0.28
growth gross profit ratio	0.03

COM:PARATEKPHARMA

Paratek Pharma

Last Close

2.19

20/09 20:00

Market Cap

127.83M

Beta: -

Volume Today

4.48M

Avg: -

Company Information

Market Metrics

Web & Growth Metrics

LTM & NTM Metrics

Growth & Performance Metrics

Operating Metrics

Balance Sheet Metrics

Financial Metrics (2022-2026)

cost and expenses	197M
cost of revenue	197M
depreciation and amortization	1.31M
ebitda	-44.9M
ebitda ratio	-0.3
eps	-1.17
eps diluted	-1.17
operating expenses	173.94M
operating income	-46.21M
operating income ratio	-0.31

accounts receivables	-40.42M
capital expenditure	-36K
cash at beginning of period	80.62M
cash at end of period	34.37M
inventory	16.57M
working capital ttm	-97.39M

	2022	2023	2024	2025	2026
Revenue Metrics
Revenue	-	-	-	-	-
Revenue Growth	-	-	-	-	-
Revenue Multiple	-	-	-	-	-
Profit Metrics
Gross Profit	-	-	-	-	-
Gross Profit Growth	-	-	-	-	-
Gross Profit Multiple	-	-	-	-	-
EBITDA Metrics
EBITDA	-	-	-	-	-
EBITDA Growth	-	-	-	-	-
EBITDA Multiple	-	-	-	-	-
Net Income Metrics
Net Income	-	-	-	-	-
Net Income Growth	-	-	-	-	-
Net Income Multiple	-	-	-	-	-